Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Cureus ; 16(8): e66233, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39238742

ABSTRACT

Bardet-Biedl syndrome (BBS) is a rare autosomal recessive ciliopathy characterized by diverse multisystem manifestations. This report discusses the unique otorhinolaryngological challenges faced by two pediatric siblings diagnosed with BBS. Case 1 involves a child with a history of chronic snoring, delayed developmental milestones, and a low intelligence quotient (IQ). The patient presented with obesity, retinitis pigmentosa, and a rare bifid epiglottis, adding to the complexity. Adenotonsillectomy was indicated due to chronic adenotonsillitis, but the presence of a grade 4 Mallampati score and restricted mouth opening required meticulous planning by the surgical and anesthesia teams. The collaborative approach led to a successful procedure, emphasizing the importance of interdisciplinary coordination in managing complex cases. Case 2, the younger sibling, presented with disturbed sleep cycles, mouth breathing, and difficulty swallowing. Adenotonsillectomy was performed for chronic adenotonsillitis, providing relief initially. However, recurrent adenoid hypertrophy, covering 90% of choanae, manifested two years later. The case highlights the need for long-term follow-up and raises questions about the underlying mechanisms contributing to recurrent adenoid hypertrophy in BBS. These cases underscore the rarity and intricacy of otorhinolaryngological manifestations in BBS, emphasizing the importance of comprehensive and multidisciplinary management. The challenges posed by anatomical abnormalities and recurrent adenoid hypertrophy necessitate ongoing research for effective long-term strategies in treating these complex genetic conditions. These findings contribute to the limited literature on BBS within the otorhinolaryngology domain and underscore the significance of continued collaboration and research efforts in optimizing patient care.

2.
Indian J Otolaryngol Head Neck Surg ; 74(Suppl 2): 2900-2905, 2022 Oct.
Article in English | MEDLINE | ID: mdl-33747892

ABSTRACT

Anosmia and ageusia are the first and maybe the only symptom in patients affected with COVID-19 especially if the patient is paucisymptomatic. This aim of this study was to determine the demographic details of patients with anosmia, prevalence of anosmia and the time taken for it to resolve in patients who are positive for COVID-19 and took treatment in our hospital. Cross Sectional Study. Patients with real time polymerase chain reaction (RTPCR) positive nasopharyngeal and oropharyngeal swabs, who met the inclusion and exclusion criteria were included in the study. The study group was interviewed through telephonic calls and a questionnaire filled to see the development and regression of their symptoms. Of the study population of 1000, 742 patients had some sort of a smell disturbance. There was a positive correlation between the severity of the disease and history of smoking. The prevalence of smell disturbances among COVID-19 patients in our study was 74.2%. One important finding that we found out was that majority of the smokers had moderate disease. Most of the patients had complete recovery form smell disturbance in the due course of time. The mean time for resolution of smell disturbance was found to be 9.89 days. Anosmia and ageusia can represent the only symptomatology present in patients with COVID-19 and they are completely reversible and hence they can be used as early predictors of infection. Level of Evidence: Level 2.

SELECTION OF CITATIONS
SEARCH DETAIL